Walter Ogier

Thetis Pharmaceuticals LLC is a biopharmaceutical company. It improves the lives of patients suffering from gastrointestinal diseases. The company’s proprietary HEALER™ technology platform enables the pharmaceutical development of bioactive lipids, including resolving and other fatty acids, that actively regulate inflammation resolution and tissue repair. Its technologies are pro-resolving lipids and intellectual property. The company was founded by Frank C. Sciavolino, Banavara L. Mylari and Gary Mathias in 2011 and is headquartered in Southport, CT.

Biothera, Inc. develops natural gluco polysaccharide that engages and directs natural innate immune systems. The company was founded by Daniel Conners in 1997 and is headquartered in Eagan, MN.

Nemucore Medical Innovations, Inc. is a clinical development company. It specializes in the development and commercialization of molecularly targeted therapeutics for the treatment of multi-drug resistant cancers with an emphasis on women's oncology. The company was founded by Timothy P. Coleman, Yuri Lvov, Vladimir Torchilin and Mansoor Amiji in 2008 and is headquartered in Wellesley, MA.

Biothera Pharmaceutical, Inc. operates as a biotechnology company. It develops Imprime PGG, a novel dectin receptor agonist that reverses tumor-mediated immunosuppression while promoting antigen presentation to drive T cell activation. The company was founded in 1997 and is headquartered in Roseville, MN.

Anelixis Therapeutics, Inc. operates as a clinical stage, privately held biotechnology company. It develops treatments for patients with neurodegenerative disease, people requiring an organ or cell based transplant, as well as people with an autoimmune disease. The company was founded by Steve Perrin in 2015 and is headquartered in Cambridge, MA.

Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA.

IRX Therapeutics, Inc. provides pharmaceutical products. Its therapies are designed to target and restore the immune system in order to improve a patient's response to next-generation cancer vaccines and novel targeted therapeutics. The company was founded in 1994 and is headquartered in New York, NY.

Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA.